摘要
目的探讨4′-甲醚-黄芩素(4-MS)对人绒毛膜癌JAR细胞的增殖抑制作用及诱导凋亡的相关机制。方法应用MTT法、激光共聚焦扫描显微镜、流式细胞术和实时定量PCR法,体外观察4-MS对JAR细胞的影响。结果不同质量浓度(10、20、40mg/L)的4-MS对JAR细胞均有增殖抑制作用,呈剂量依赖,作用72h后其增殖抑制率分别为(14.14±0.75)%、(34.34±2.99)%、(61.11±2.99)%(P<0.01);4-MS作用72h后细胞内Ca2+浓度分别为81.3±6.7、103.3±5.9、120.7±11.0,与对照组相比差异有显著性(P<0.05)。40mg/L4-MS作用12、24、36h后其早期凋亡率分别为(2.36±0.19)%、(4.22±2.44)%、(7.34±0.56)%,明显高于对照组(P<0.01)。20、40mg/L4-MS作用48h后hTERT mRNA的表达量为0.05±0.01和0.02±0.01,明显低于对照组(P<0.01)。结论4-MS能抑制人绒毛膜癌JAR细胞的增殖,诱导凋亡,其机制与提高细胞内Ca2+浓度、降低hTERT mRNA的表达有关。
Objective To investigate the inhibition and the mechanism of apoptosis inducement to the cell proliferation by 4＇-methyl ether-scutellarein （4-MS） on human choriocarcinoma JAR cell line. Methods The techniques of MTT assay, flow cytometry, laser scanning confocal microscopy （LSCM）, and real-time quantitative PCR were used to study the effect of 4-MS on JAR cells in vitro. Results 4-MS had does- and time-dependent inhibitory effects on proliferation of JAR cells. After the JAR cells were treated by 4-MS in different concentrations （10, 20, and 40 mg/L） for 72 h, the inhibitory rates were （14.14±0.75）%, （34.34±2.99）%, and （61.11±2.99）% （P〈0.01）, and the intracellular Ca^2＋ concentrations were 81.3±6.7, 103.3±5.9, and 120.7±11.0, with the significant difference compared to the control group （P〈0.05）, respectively. After the JAR cells were treated by 4-MS （40 mg/L） for 12, 24, and 36 h, the early apoptosis rates were （2.36±0.19）%, （4.22±2.44）%, and （7.34±0.56）%, much higher than that in the control group （P〈0.01）, respectively. After the JAR cells were treated by 4-MS （20 and 40 mg/L） for 48 h, the expressions of hTERT mRNA were 0.05±0.01 and 0.02±0.01, much lower than that in the control group （P〈0.01）. Conclusion The proliferation can be inhibited and the apoptosis of human choriocarcinoma JAR cell line can be induced by 4-MS. Its mechanism is related to the increase of intracellular Ca^2＋ concentration and the decrease of hTERT mRNA expression.
出处
《中草药》
CAS
CSCD
北大核心
2007年第8期1203-1206,共4页
Chinese Traditional and Herbal Drugs
基金
江苏省自然科学基金资助项目(BK2003104)
